Carotid body tumor screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 29: | Line 29: | ||
{{familytree | | | | | | H02 |-|'| | | |H02=All the relatives should be evaluated for the presence of paragnaglioma}} | {{familytree | | | | | | H02 |-|'| | | |H02=All the relatives should be evaluated for the presence of paragnaglioma}} | ||
{{Family tree | | | | | | |!| | | | }} | {{Family tree | | | | | | |!| | | | }} | ||
{{Family tree | | | | | | I01 | | | |I01= whole-body | {{Family tree | | | | | | I01 | | | |I01= whole-body F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas}} | ||
{{Family tree | | | |,|-|-|^|-|-|.| |}} | {{Family tree | | | |,|-|-|^|-|-|.| |}} | ||
{{Family tree | | | J01 | | | | J02 |J01= Presence of other paraganglioma |J02= Absence of other paraganglioma}} | {{Family tree | | | J01 | | | | J02 |J01= Presence of other paraganglioma |J02= Absence of other paraganglioma}} | ||
Revision as of 20:33, 8 April 2019
|
Carotid body tumor Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carotid body tumor screening On the Web |
|
American Roentgen Ray Society Images of Carotid body tumor screening |
|
Risk calculators and risk factors for Carotid body tumor screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Overview
There is insufficient evidence to recommend routine screening for the carotid body tumor. However, patients who manifested the symptoms before the age of 50 years old, those with a positive family history and those with multiple paragangliomas has been recommended to undergo additional testing.
Screening
- There is insufficient evidence to recommend routine screening for the carotid body tumor. However, it has been recommended that the following patients should undergo additional evaluations:[1]
- Patients younger than 50 years of age
- Patients with a positive family history for paraganglioma
- Patients with multiple paragangliomas
| Patient with carotid body tumor | |||||||||||||||||||||||||||||||||||
| History, Physical examination, and evaluation of cnotralateral side | |||||||||||||||||||||||||||||||||||
| Patients with age < 50 years Patients with multiple paraganglioma Patients with a positive family history | The rest of the patients | ||||||||||||||||||||||||||||||||||
| SDHD genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHD mutation | Absence of SDHD mutation | ||||||||||||||||||||||||||||||||||
| SDHC and SDHB genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHC/B mutation | Absence of SDHC/B mutation | ||||||||||||||||||||||||||||||||||
| All the relatives should be evaluated for the presence of paragnaglioma | |||||||||||||||||||||||||||||||||||
| whole-body F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas | |||||||||||||||||||||||||||||||||||
| Presence of other paraganglioma | Absence of other paraganglioma | ||||||||||||||||||||||||||||||||||
| 24-hour urine catecholamines and MRI for biochemical screening | surveillance screening every 5 years | ||||||||||||||||||||||||||||||||||
- In case of functional paraganglioma, the patient should receive a-blockade, followed by b-blockade for symptom control before excision of the tumor.
References
- ↑ Davila, Victor J.; Chang, James M.; Stone, William M.; Fowl, Richard J.; Bower, Thomas C.; Hinni, Michael L.; Money, Samuel R. (2016). "Current surgical management of carotid body tumors". Journal of Vascular Surgery. 64 (6): 1703–1710. doi:10.1016/j.jvs.2016.05.076. ISSN 0741-5214.